KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Other Non Operating Income (2023 - 2026)

Fulgent Genetics' Other Non Operating Income history spans 4 years, with the latest figure at $10000.0 for Q1 2026.

  • On a quarterly basis, Other Non Operating Income fell 85.29% to $10000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $95000.0, a 84.92% decrease, with the full-year FY2025 number at $153000.0, down 72.73% from a year prior.
  • Other Non Operating Income hit $10000.0 in Q1 2026 for Fulgent Genetics, down from $44000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for FLGT hit a ceiling of $544000.0 in Q3 2024 and a floor of -$22000.0 in Q4 2023.
  • Historically, Other Non Operating Income has averaged $85272.7 across 4 years, with a median of $11000.0 in 2024.
  • The widest YoY moves for Other Non Operating Income: up 855.56% in 2025, down 100.92% in 2025.
  • Tracing FLGT's Other Non Operating Income over 4 years: stood at -$22000.0 in 2023, then skyrocketed by 131.82% to $7000.0 in 2024, then skyrocketed by 528.57% to $44000.0 in 2025, then plummeted by 77.27% to $10000.0 in 2026.
  • Business Quant data shows Other Non Operating Income for FLGT at $10000.0 in Q1 2026, $44000.0 in Q4 2025, and -$5000.0 in Q3 2025.